Alemtuzumab demonstrates persistent clinical efficacy outcomes over 5 years in patients with active relapsing-remitting multiple sclerosis, with most not receiving retreatment: CARE-MS I and II extension studies

Eva Havrdova¹, Douglas L. Arnold²,³, D. Alastair S. Compston⁴, Hans-Peter Hartung⁵, Krzysztof W. Selmaj⁶, Linda Kasten⁷, and David H. Margolin⁸ on behalf of the CARE-MS I and CARE-MS II Investigators

Background: Patients with active relapsing-remitting multiple sclerosis (RRMS) who were treatment-naive (CARE-MS I; NCT00530348) or with inadequate response (≥1 relapse) to prior therapy (CARE-MS II; NCT00548405) had improved outcomes with alemtuzumab versus SC IFNB-1a over 2 years.

Objective: To examine alemtuzumab’s efficacy and safety over 5 years in CARE-MS patients.

Methods: Patients received 2 courses of alemtuzumab 12 mg (Months 0 and 12), with as-needed retreatment for disease activity, or another disease-modifying therapy (DMT). Annualised relapse rate (ARR), 6-month confirmed disability progression (≥1-point Expanded Disability Status Scale [EDSS] increase [≥1.5-point if baseline EDSS=0]), and 6-month sustained reduction in pre-existing disability (SRD; ≥1-point EDSS decrease [baseline ≥2.0]) were assessed.

Results: 349 (95%) and 393 (93%) CARE-MS I and II patients entered extension (NCT00930553), respectively; 68% and 60% received no alemtuzumab since initial 2 courses; 98% and 92% received no other DMT. ARRs remained low from Year 3 (0.19 and 0.22) to Year 5 (0.15 and 0.18). Through Years 0–5, 80% and 75% were free from 6-month confirmed disability progression, and 33% and 43% achieved 6-month SRD. Infusion-associated reactions and infections were reduced versus core studies, and serious adverse events (AE) were low. Thyroid AEs peaked at Year 3, then declined.

Conclusions: Alemtuzumab improved relapse and disability outcomes over 5 years despite most patients not receiving retreatment. Based on these findings, for the majority of RRMS patients, alemtuzumab may provide an innovative treatment approach with efficacy persisting through 5 years in the absence of continued treatment and associated treatment burden.

Abstract

Citation: Havrdova et al. Alemtuzumab demonstrates persistent clinical efficacy outcomes over 5 years in patients with active relapsing-remitting multiple sclerosis, with most not receiving retreatment: CARE-MS I and II extension studies. International Journal of Clinical Neurosciences and Mental Health 2016; 3(Suppl. 1):P9

Published: 16 March 2016